Sort
4,870 grants matching “glp 1”
Iron Chelators Predicated on Desferrithiocin
$579,179Raymond J Bergeron · University Of Florida · R37 · FY2006 · DK
Advancing a Lead Candidate Hantavirus Pulmonary Syndrome DNA Vaccine
$578,793Jay Williams Hooper · Geneva Foundation · R01 · FY2016 · AI
PIC1 pre-clinical formulation and optimization as a novel anti-inflammatory pharmacological agent
$578,570Neel Kumar Krishna · Realta Life Sciences, Inc. · R44 · FY2020 · AI
The Role of Phosphodiesterase Inhibitors in Incretin Secretion
$576,682Chee W Chia · National Institute On Aging · ZIA · FY2015 · AG
Studies in Youths & Young Adults with Obesity & T2DM (07-DK-0115, 10-DK-0163)
$576,464Marc L Reitman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2011 · DK
Encapsulated Porcine Islets into Rhesus Macaques
$576,311Ingrid Stuiver · Microislet, Inc. · R44 · FY2007 · DK
Durable Muscle-Prosthetic Bond for Artificial Tendons
$575,816Natalia Juncosa-Melvin · Cardioenergetics, Inc. · R44 · FY2009 · AR
Preclinical Test of Biodefense Drug for SEB Toxin
$575,618Viral Genomix, Inc. · R43 · FY2005 · AI
A reversible aptamer based therapeutic to treat stroke
$575,406Richard Joseph Shea · Basking Biosciences · R44 · FY2020 · HL
University of Maryland, Baltimore Biomarker Reference Laboratory
$575,204Sanford A Stass · University Of Maryland Baltimore · U24 · FY2018 · CA
PSMA-VRP vaccine for prostate cancer
$574,893William C Olson · Progenics Pharmaceuticals, Inc. · R44 · FY2008 · CA
Iron Chelators Predicated on Desferrithiocin
$574,142Raymond J Bergeron · University Of Florida · R37 · FY2009 · DK
Integration of Genomic Biomarkers with the devTOX Human Embryonic Stem Cells Scre
$573,697Leslie Recio · Integrated Laboratory Systems, Llc · R44 · FY2014 · ES
EGFRwt and EGFRvlll Dual-Specific Immunotoxin for Glioblastoma Multiforme
$573,030Darell D Bigner · Duke University · P01 · FY2013 · CA
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
$572,502Gerardo Guillermo Mackenzie · University Of California At Davis · R01 · FY2025 · CA
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients
$571,983Frank Sciavolino · Thetis Pharmaceuticals, Llc · R44 · FY2019 · DK
Optimization of a Combined Drug and Delivery Device for Treatment of Cyanide Poisoning
$571,768Steven E Patterson · University Of Minnesota · U01 · FY2019 · NS
GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine
$571,691Ellen Elizabeth Sparger · Tendel Therapies Inc. · R44 · FY2024 · AI
A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis
$571,536Christina Grek · Regranion, Llc · R44 · FY2018 · AR
Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin
$570,747Koon Y Pak · Molecular Targeting Technologies, Inc. · R01 · FY2020 · CA
Iron Chelators Predicated on Desferrithiocin
$570,179Raymond J Bergeron · University Of Florida · R37 · FY2007 · DK
Imaging beta cell function for metabolic surgery
$570,151Paul E Harris · Columbia University Health Sciences · R01 · FY2015 · DK
Encapsulated Porcine Islets into Rhesus Macaques
$569,778Ingrid Stuiver · Microislet, Inc. · R44 · FY2006 · DK
Impact of GLP-1 on Hepatic Fat and Energy Utilization in Obese Girls with Polycystic Ovarian Syndrome
$569,139Melanie G Cree · University Of Colorado Denver · R01 · FY2020 · DK
Second generation GLP-1 agonists without nausea/emesis side effects
$569,065Matthew R Hayes · University Of Pennsylvania · R01 · FY2024 · DK